Screener
Dianthus Therapeutics DNTH Stock-Based Comp
Stock-Based Comp at other companies
Other financials
Where this comes from
Reported directly by Dianthus Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The source filing: Dianthus Therapeutics’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:06 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001690585-26-000022
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Net loss | $(40,834) | $(29,511) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation expense | 32 | 27 |
| Stock-based compensation expense | 10,602 | 5,315 |
| Accretion of discount on investment securities | (1,218) | (1,899) |
| Amortization of right-of-use operating lease assets | 44 | 106 |
| Loss on investment in former related party | 302 | (5) |
| Changes in operating assets and liabilities: |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Dianthus Therapeutics's stock-based comp?
- Dianthus Therapeutics (DNTH) reported stock-based comp of $10.6M in Q1 2026.
- How has Dianthus Therapeutics's stock-based comp changed year-over-year?
- Dianthus Therapeutics's stock-based comp increased by 99.5% year-over-year, from $5.32M to $10.6M.
- What is the long-term trend for Dianthus Therapeutics's stock-based comp?
- Over 2 years (2021 to 2024), Dianthus Therapeutics's stock-based comp has grown at a 11.8% compound annual growth rate (CAGR), from $10.31M to $12.89M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.
Ask your AI about Dianthus Therapeutics's stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude